Jacobs Levy Equity Management’s Ginkgo Bioworks DNA Stock Holding History

Jacobs Levy Equity Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$609K	Sell	61,461 -261,256	-81%	-$2.18M	﹤0.01%	799
2026 Q1	$1.98M	Buy	322,717 +78,298	+32%	+$651K	0.01%	591
2025 Q4	$2.03M	Buy	244,419 +173,552	+245%	+$1.87M	0.01%	578
2025 Q3	$1.03M	Buy	+70,867	New	+$848K	﹤0.01%	709
2024 Q4	–	Sell	-279,954	Closed	-$2.28M	–	961
2024 Q3	$2.28M	Buy	+279,954	New	+$2.81M	0.01%	581
2024 Q1	–	Sell	-6,408	Closed	-$433K	–	962
2023 Q4	$433K	Hold	6,408	–	–	﹤0.01%	847
2023 Q3	$464K	Sell	6,408 -86,593	-93%	-$6.92M	﹤0.01%	814
2023 Q2	$6.92M	Sell	93,001 -76,074	-45%	-$4.5M	0.04%	330
2023 Q1	$8.99M	Buy	+169,075	New	+$10.7M	0.06%	300

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Jacobs Levy Equity Management's DNA Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its Ginkgo Bioworks (DNA) stake by 81% in Q2 2026, selling an estimated $2.18M and leaving 61,461 shares worth $609K. The position accounts for ﹤0.01% of the portfolio, ranked #799.

Jacobs Levy Equity Management first reported a position in DNA in Q1 2023 and has held it in 9 quarters since. The position peaked at $8.99M in Q1 2023. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

Jacobs Levy Equity Management held 61,461 shares of Ginkgo Bioworks worth $609K as of Q2 2026.
Jacobs Levy Equity Management sold 261,256 Ginkgo Bioworks shares in Q2 2026, an estimated $2.18M.
Ginkgo Bioworks made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #799 holding.
Jacobs Levy Equity Management first reported a position in Ginkgo Bioworks in Q1 2023 and has held it in 9 quarters since.
Jacobs Levy Equity Management's Ginkgo Bioworks position peaked at $8.99M in Q1 2023.
184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.